Literature DB >> 2816996

Autism is not associated with the fragile X syndrome.

S Einfeld1, H Molony, W Hall.   

Abstract

We provided a controlled test of the hypothesis that individuals with the Martin-Bell or Fragile X [fra(x)] syndrome are more autistic than mentally retarded control individuals. A sample of fra(x) individuals was obtained from the register of a clinical genetics unit and compared with mentally retarded control individuals selected from an assessment centre who were individually matched for age, sex, and IQ. A comparison of 45 pairs of fra(x) cases and control individuals on the DSM-III (R) criteria for autism and two standardized "instruments" for the assessment of autism (ABC and ADC) failed to find a higher prevalence of autism among fra(x) individuals. There was no statistically significant difference between fra(x) individuals and control individuals, and the mean differences on both the ABC and ADC scales were in the direction contrary to the hypothesis. An analysis of the study's statistical power suggested that it is unlikely the investigation failed to detect a large to medium difference between fra(x) individuals and control individuals in autistic behaviour. Subsidiary analyses of case-control differences showed that two autistic-like behaviours occurred at a higher rate among fra(x) individuals than other mentally retarded children, namely, gaze avoidance and hand flapping. These abnormalities may have misled clinicians into thinking that autism and fra(x) are associated.

Entities:  

Mesh:

Year:  1989        PMID: 2816996     DOI: 10.1002/ajmg.1320340211

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

1.  Longitudinal changes in cognitive and adaptive behavior scores in children and adolescents with the fragile X mutation or autism.

Authors:  Gene S Fisch; Richard J Simensen; R J Schroer
Journal:  J Autism Dev Disord       Date:  2002-04

2.  Autism in fragile X syndrome: a category mistake?

Authors:  Scott S Hall; Amy A Lightbody; Melissa Hirt; Ava Rezvani; Allan L Reiss
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-08-01       Impact factor: 8.829

Review 3.  Specific genetic disorders and autism: clinical contribution towards their identification.

Authors:  David Cohen; Nadège Pichard; Sylvie Tordjman; Clarisse Baumann; Lydie Burglen; Elsa Excoffier; Gabriela Lazar; Philippe Mazet; Clément Pinquier; Alain Verloes; Delphine Héron
Journal:  J Autism Dev Disord       Date:  2005-02

Review 4.  Brief report: low frequency of the fragile X syndrome among Japanese autistic subjects.

Authors:  O Hashimoto; Y Shimizu; Y Kawasaki
Journal:  J Autism Dev Disord       Date:  1993-03

5.  Autistic behaviors among girls with fragile X syndrome.

Authors:  M M Mazzocco; W R Kates; T L Baumgardner; L S Freund; A L Reiss
Journal:  J Autism Dev Disord       Date:  1997-08

6.  Association study with two markers of a human homeogene in infantile autism.

Authors:  E Petit; J Hérault; J Martineau; A Perrot; C Barthélémy; L Hameury; D Sauvage; G Lelord; J P Müh
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

7.  Hyperactivity and the fragile X syndrome.

Authors:  S Einfeld; W Hall; F Levy
Journal:  J Abnorm Child Psychol       Date:  1991-06

Review 8.  Autism: the point of view from fragile X studies.

Authors:  C Feinstein; A L Reiss
Journal:  J Autism Dev Disord       Date:  1998-10

9.  Examining the Overlap between Autism Spectrum Disorder and 22q11.2 Deletion Syndrome.

Authors:  Opal Ousley; A Nichole Evans; Samuel Fernandez-Carriba; Erica L Smearman; Kimberly Rockers; Michael J Morrier; David W Evans; Karlene Coleman; Joseph Cubells
Journal:  Int J Mol Sci       Date:  2017-05-18       Impact factor: 5.923

Review 10.  Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy.

Authors:  Cyrille Robert; Laurent Pasquier; David Cohen; Mélanie Fradin; Roberto Canitano; Léna Damaj; Sylvie Odent; Sylvie Tordjman
Journal:  Int J Mol Sci       Date:  2017-03-12       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.